These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11881528)

  • 1. Daptomycin. Cidecin, Dapcin, LY 146032.
    Drugs R D; 2002; 3(1):33-9. PubMed ID: 11881528
    [No Abstract]   [Full Text] [Related]  

  • 2. Antimicrobial update: Daptomycin.
    Oberholzer CM; Caserta MT
    Pediatr Infect Dis J; 2005 Oct; 24(10):919-20. PubMed ID: 16220092
    [No Abstract]   [Full Text] [Related]  

  • 3. Pre-clinical experience with daptomycin.
    Hawkey PM
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii7-14. PubMed ID: 18829726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Daptomycin. Reassessment of an antibiotic].
    Gobernado M
    Rev Esp Quimioter; 2007 Mar; 20(1):11-8. PubMed ID: 17530032
    [No Abstract]   [Full Text] [Related]  

  • 5. Early experience with high-dosage daptomycin for prosthetic infections.
    De Rosa FG; Mollaretti O; Cometto C; Pagani N; Montrucchio C; Di Perri G
    Clin Infect Dis; 2009 Dec; 49(11):1772-3. PubMed ID: 19891570
    [No Abstract]   [Full Text] [Related]  

  • 6. Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology.
    Wesson KM; Lerner DS; Silverberg NB; Weinberg JM
    Dis Mon; 2004 Jul; 50(7):395-406. PubMed ID: 15280870
    [No Abstract]   [Full Text] [Related]  

  • 7. Daptomycin-induced rhabdomyolysis and acute liver injury.
    King ST; Walker ED; Cannon CG; Finley RW
    Scand J Infect Dis; 2014 Jul; 46(7):537-40. PubMed ID: 24801642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daptomycin, a lipopeptide antibiotic in clinical practice.
    Weis F; Beiras-Fernandez A; Schelling G
    Curr Opin Investig Drugs; 2008 Aug; 9(8):879-84. PubMed ID: 18666036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The second life of daptomycin: analysis of a successful come-back].
    Decousser JW; Doucet Populaire F
    Med Mal Infect; 2008 Dec; 38 Spec No 2():1-3. PubMed ID: 19185200
    [No Abstract]   [Full Text] [Related]  

  • 10. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
    Steenbergen JN; Alder J; Thorne GM; Tally FP
    J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of daptomycin for Staphylococcus aureus infections in critical care medicine.
    Alder J
    Crit Care Clin; 2008 Apr; 24(2):349-63, ix-x. PubMed ID: 18361950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current use of daptomycin and systematic therapeutic drug monitoring: Clinical experience in a tertiary care institution.
    Galar A; Muñoz P; Valerio M; Cercenado E; García-González X; Burillo A; Sánchez-Somolinos M; Juárez M; Verde E; Bouza E
    Int J Antimicrob Agents; 2019 Jan; 53(1):40-48. PubMed ID: 30243587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
    Rybak MJ
    Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of cSSTIs: the role of daptomycin.
    Garau J
    Curr Med Res Opin; 2006 Nov; 22(11):2079-87. PubMed ID: 17076967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections.
    Di Paolo A; Tascini C; Polillo M; Gemignani G; Nielsen EI; Bocci G; Karlsson MO; Menichetti F; Danesi R
    Int J Antimicrob Agents; 2013 Sep; 42(3):250-5. PubMed ID: 23891432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Daptomycin: revitalizing a former drug due to the need of new active agents against grampositive multiresistant bacterias].
    Hernández Martí V; Romá Sánchez E; Salavert Lletí M; Bosó Ribelles V; Poveda Andrés JL
    Rev Esp Quimioter; 2007 Sep; 20(3):261-76. PubMed ID: 18080024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A new in star in antibiotic heaven--daptomycin].
    Holzgrabe U
    Pharm Unserer Zeit; 2004; 33(4):270. PubMed ID: 15287683
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic challenges in the era of antibiotic resistance.
    Lee C
    Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S197-9. PubMed ID: 19134519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing daptomycin expenditures by standardizing doses.
    Memoli D; Shepardson A; Joshi M; Heil E
    Am J Health Syst Pharm; 2014 Jan; 71(1):12, 14. PubMed ID: 24352176
    [No Abstract]   [Full Text] [Related]  

  • 20. Daptomycin: a new drug class for the treatment of Gram-positive infections.
    Alder JD
    Drugs Today (Barc); 2005 Feb; 41(2):81-90. PubMed ID: 15821781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.